|
|
|
|
| LEADER |
02386nam a2200325 u 4500 |
| 001 |
EB001999459 |
| 003 |
EBX01000000000000001162360 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Fluocinolone acetonide intravitreal implant (Iluvien) (Knight Therapeutics Inc.)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Fluocinolone acetonide intravitreal implant (Iluvien) (Knight Therapeutics Inc.)
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for Iluvien
|
| 250 |
|
|
|a Version: final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c October 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (34 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Macular Edema / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Intravitreal Injections
|
| 653 |
|
|
|a Fluocinolone Acetonide / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Indication: For the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure."
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK551922
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Fluocinolone acetonide (FA) intravitreal implant (Iluvien), a corticosteroid, is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Iluvien is a non-biodegradable 0.19 mg intravitreal implant with a submitted price of $7,770 per implant. The recommended dosing schedule is one implant, which is designed to release FA over three years at a rate of approximately 0.2 mcg per day. FA implant was previously reviewed by CADTH in 2018. The manufacturer, however, chose to withdraw the submission during the review period. The manufacturer submitted a cost-utility analysis (CUA) that modelled patients with DME who had received at least one prior laser treatment as per the three-year FAME trials
|